Literature DB >> 21921783

Immunohistochemical staining of thyroidectomy specimens for PTEN can aid in the identification of patients with Cowden syndrome.

Justine A Barletta1, Andrew M Bellizzi, Jason L Hornick.   

Abstract

Cowden syndrome (CS) is an autosomal dominant disorder caused by a germline mutation in PTEN (phosphatase and tensin homolog, deleted on chromosome 10) and characterized by the development of multiple hamartomas and carcinomas of the thyroid, breast, and uterus. Recognition of CS is important so that cancer screening and genetic counseling can be initiated. Pathologic findings in thyroidectomy specimens suggestive of, but not specific for, CS include multiple adenomatous nodules, follicular adenomas, and nodular hyperplasia, with or without follicular carcinoma or papillary thyroid carcinoma. The aim of our study was to determine whether immunohistochemical staining for PTEN could aid in the identification of CS in patients with these pathologic findings. We studied 21 thyroidectomy specimens from patients with a known history of CS or with pathologic findings that raised the possibility of CS. Immunohistochemistry for PTEN was performed on all cases, and assessment of PTEN expression was performed by a pathologist blinded to the clinical history and recorded as follows: intact expression in all lesional nodules, complete loss of expression in all lesional nodules, or heterogeneous loss of expression, with some nodules showing intact expression and other nodules showing complete loss of expression. Nine cases showed loss of PTEN expression, and 12 cases showed intact expression. Of the 9 cases that showed loss of PTEN expression, 8 patients were CS patients (5 showed complete loss of staining in all nodules, and 3 showed heterogeneous loss of staining), and 1 patient was determined not to have CS (this patient had a history of radiation treatment). Of the 12 patients whose thyroidectomy specimens showed intact PTEN expression, none had CS by clinical history, family history, or genotyping. Thus, the sensitivity and specificity of PTEN staining for the detection of CS are 100% and 92.3%, respectively. In summary, loss of PTEN expression in adenomatous thyroid nodules, whether in all nodules or in a subset of nodules, appears to be both sensitive and specific for CS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21921783     DOI: 10.1097/PAS.0b013e31822fbc7d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).

Authors:  Thomas G Papathomas; Lindsey Oudijk; Alexandre Persu; Anthony J Gill; Francien van Nederveen; Arthur S Tischler; Frédérique Tissier; Marco Volante; Xavier Matias-Guiu; Marcel Smid; Judith Favier; Elena Rapizzi; Rosella Libe; Maria Currás-Freixes; Selda Aydin; Thanh Huynh; Urs Lichtenauer; Anouk van Berkel; Letizia Canu; Rita Domingues; Roderick J Clifton-Bligh; Magdalena Bialas; Miikka Vikkula; Gustavo Baretton; Mauro Papotti; Gabriella Nesi; Cécile Badoual; Karel Pacak; Graeme Eisenhofer; Henri J Timmers; Felix Beuschlein; Jérôme Bertherat; Massimo Mannelli; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Winand Nm Dinjens; Esther Korpershoek; Ronald R de Krijger
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

2.  Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations.

Authors:  Scott K Sherman; Jessica E Maxwell; Qining Qian; Andrew M Bellizzi; Terry A Braun; Mark D Iannettoni; Benjamin W Darbro; James R Howe
Journal:  Cancer Genet       Date:  2014-11-15

Review 3.  Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: DICER1-Related Thyroid Tumors.

Authors:  Madeline Sauer; Justine A Barletta
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 4.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 5.  Overview of the 2022 WHO Classification of Thyroid Neoplasms.

Authors:  Zubair W Baloch; Sylvia L Asa; Justine A Barletta; Ronald A Ghossein; C Christofer Juhlin; Chan Kwon Jung; Virginia A LiVolsi; Mauro G Papotti; Manuel Sobrinho-Simões; Giovanni Tallini; Ozgur Mete
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 3.943

6.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

Review 7.  Genodermatosis Affecting the Skin and Mucosa of the Head and Neck: Clinicopathologic, Genetic, and Molecular Aspect--PTEN-Hamartoma Tumor Syndrome/Cowden Syndrome.

Authors:  Vania Nosé
Journal:  Head Neck Pathol       Date:  2016-03-14

8.  Familial follicular cell-derived thyroid carcinoma.

Authors:  Eun Ju Son; Vânia Nosé
Journal:  Front Endocrinol (Lausanne)       Date:  2012-05-03       Impact factor: 5.555

Review 9.  Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?

Authors:  Adele Wong; Joanne Ngeow
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

Review 10.  Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.

Authors:  José Manuel Cameselle-Teijeiro; Ozgur Mete; Sylvia L Asa; Virginia LiVolsi
Journal:  Endocr Pathol       Date:  2021-01-25       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.